Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →A grade PMID 42248607
View analysis →A grade PMID 41667193
View analysis →This systematic review reports that pediatric chemotherapy protocols may improve survival in adults with rhabdomyosarcoma, while evidence for Ewing sarcoma and osteosarcoma is limited, and that adults generally receive lower chemotherapy exposure and experience different toxicity patterns than children.
The evidence supports an association between pediatric-protocol treatment and improved survival in one non-metastatic adult rhabdomyosarcoma cohort; inferentially, maintaining adequate chemotherapy exposure and including disease-specific agents could improve adult sarcoma outcomes, but this requires confirmation in prospective studies and careful toxicity assessment.
This retrospective international multicenter study reports that, among patients with unresectable hepatocellular carcinoma and Child-Pugh B cirrhosis, atezolizumab/bevacizumab was associated with longer survival than sorafenib and that ALBI grade 1/2 without extrahepatic metastasis identified a subgroup with better outcomes.
The record supports an association between preserved liver function, absence of extrahepatic metastasis, and better outcomes with first-line atezolizumab/bevacizumab; it remains an inference requiring prospective validation that selecting patients by these features and actively treating underlying liver disease will improve survival.
This narrative review synthesizes preclinical and translational evidence that fatty acid oxidation, amino acid metabolism, mitochondrial dynamics, oxidative phosphorylation, and the kynurenine–AHR axis support brain-tumor survival, resistance, and immune evasion and may provide combination-treatment targets.
The reviewed evidence suggests that inhibiting selected non-glycolytic metabolic dependencies may sensitize metabolically defined brain tumors to radiotherapy, immunotherapy, or other treatments; this remains an inferred therapeutic strategy requiring brain-penetrant agents, biomarkers, and prospective clinical validation.
In this adult phase 3 HCC trial, adding STRIDE immunotherapy and lenvatinib to TACE significantly improved progression-free survival versus TACE alone, but overall survival was not significantly improved at the reported cutoff and serious adverse events were more frequent with the triplet regimen.
Evidence: STRIDE plus lenvatinib plus TACE reduced the risk of progression or death relative to TACE in embolisation-eligible adult HCC (HR 0.70), while an overall-survival benefit remained unproven and toxicity increased. Inference: combining checkpoint blockade and anti-angiogenic therapy with embolisation might improve disease control, but applicability to pediatric liver cancers cannot be inferred from this adult-only record.
This retrospective single-center study of 102 pediatric patients with very-high-risk or high-risk rhabdomyosarcoma found no significant differences in remission duration or 2-year event-free survival among three maintenance approaches, reported no grade 3 or higher treatment-related adverse events, and associated PAX-FOXO1 fusion, CDK4 mutation, and TP53 mutation with unfavorable remission duration.
The evidence supports the feasibility and potential prognostic value of targeted-drug and oral-chemotherapy maintenance strategies, including longitudinal ctDNA monitoring; it remains an inference—not proof—that ctDNA-guided maintenance selection could improve outcomes, because the retrospective nonrandomized comparisons did not establish efficacy equivalence or clinical utility.
This review synthesizes osteosarcoma-specific and extrapolated evidence for oncolytic vectors, engineered immune cells, antigen-directed strategies, and non-viral gene delivery, while outlining combination approaches, knowledge gaps, and the clinical-trial landscape.
The supplied evidence shows limited checkpoint-inhibitor activity in unselected osteosarcoma and describes several barriers to antitumor immunity; the inferred therapeutic hypothesis is that gene-based platforms could overcome these barriers by inducing antigen release, delivering local immune signals, or engineering tumor recognition, although efficacy and safety in pediatric osteosarcoma remain unestablished.
In a multicenter phase III trial of 258 patients aged 18–75 years with newly diagnosed grade 3 or 4 glioma, reducing the adjuvant radiotherapy CTV margin from 2 cm to 1 cm did not significantly alter PFS, OS, or recurrence distribution, although survival estimates numerically favored the standard-margin group.
The trial provides evidence that a 1-cm CTV margin does not significantly increase marginal or out-of-field recurrence; it may therefore reduce irradiation of normal brain while preserving disease control, but reduced toxicity was not reported and the confidence intervals and numerical survival trends do not establish equivalence or noninferiority.
This article reviews the development, manufacture, clinical results, obstacles, and future combination strategies for adoptive cell therapies in pediatric solid tumors.
The supplied record reports clinical experience supporting evaluation of adoptive cell therapy safety, feasibility, and efficacy; it further infers that improved cell products and combination therapies could overcome solid-tumor barriers while potentially limiting acute and long-term toxicity, but no specific effective regimen is established in the abstract.
In a national cohort of 225 children and young people receiving frontline blinatumomab for chemotherapy-intolerant or resistant B-ALL, post-cycle-1 MRD and selected genetic features identified relapse risk more effectively than conventional chemotherapy-era factors.
The cohort provides evidence that cycle-1-end MRD, IKZF1plus, and DUX4 rearrangement can stratify relapse risk after frontline blinatumomab; it is an inference requiring prospective validation that this model could safely guide treatment intensification for high-risk patients or de-intensification for those without these features.
This record reports the design of a 284-participant randomized, open-label trial comparing structured supervised exercise with exercise recommendations for prevention of treatment-related cardiac dysfunction in adult women receiving anthracyclines and/or trastuzumab for stage I–III breast cancer.
The planned trial will test whether structured aerobic and resistance exercise reduces biomarker- or imaging-defined cardiac dysfunction relative to exercise advice alone; any preventive benefit, quality-of-life improvement, or applicability to pediatric oncology remains hypothetical because no results are reported and eligibility begins at age 18.
This case report describes a 54-year-old man with ruptured, multifocal unresectable HCC who had four years of stable disease on intralesional Pexa-Vec plus nivolumab, subsequently underwent liver transplantation, and remained free of recurrence and graft rejection at 24 months.
Evidence from this single adult case shows prolonged disease control, necrosis or regression in tumor lesions, and successful transplantation after withdrawal of combined oncolytic virotherapy and PD-1 blockade; it is an inference—not established efficacy—that this regimen could downstage selected advanced HCC patients or bridge them to transplantation.
This systematic review pooled 60 published cases of immune checkpoint inhibitor-associated central nervous system demyelinating disease, characterizing presentations, timing, management, outcomes, and a 16.7% relapse frequency.
The evidence shows that most reported patients received corticosteroids and discontinued checkpoint inhibition, with 71.7% reported to have favorable outcomes; it is reasonable but not proven to hypothesize that early syndrome recognition, antibody testing, and prompt individualized immunosuppression could reduce neurological morbidity or relapse.
